A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma

被引：0
|
作者：
Nagao, S. [1 ]
Oishi, R. [1 ]
Iwasa, N. [1 ]
Shimizu, M. [1 ]
Hasegawa, K. [1 ]
Goto, T. [1 ]
Fujiwara, K. [1 ]
机构：
[1] Saitama Med Univ Int, Med Ctr, Hidaka City, Saitama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16549
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
    Landrum, Lisa M.
    Hyde, Johnny, Jr.
    Mannel, Robert S.
    McMeekin, D. Scott
    Moore, Kathleen N.
    Walker, Joan L.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (03) : 527 - 531
  • [32] Paclitaxel-based chemotherapy in carcinoma of the Fallopian tube
    Gemignani, ML
    Hensley, ML
    Cohen, R
    Venkatraman, E
    Saigo, PE
    Barakat, RR
    GYNECOLOGIC ONCOLOGY, 2001, 80 (01) : 16 - 20
  • [33] Survival and toxicity of a modified GOG 172 IP chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma
    Becker, D.
    Haygood, C. L. Walters
    Smith, B.
    Bevis, K. S.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 177
  • [34] Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
    Mullany, Sally
    Miller, David Scott
    Robison, Katina
    Levinson, Kimberly
    Lee, Yi-Chun
    Yamada, S. Diane
    Walker, Joan
    Markman, Maurie
    Marin, Alyson
    Mast, Peter
    diZerega, Gere
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 34
  • [35] Liposomal doxorubicin in sequential doublet combination with paclitaxel and carboplatin in patients with primary epithelial ovarian or primary peritoneal carcinoma.
    Method, MW
    Rodriguez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 472S - 472S
  • [36] A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.
    Konner, Jason A.
    Boucicaut, Nicole N.
    O'Cearbhaill, Roisin Eilish
    Zamarin, Dmitriy
    Makker, Vicky
    Sabbatini, Paul
    Tew, William P.
    Cadoo, Karen Anne
    Grisham, Rachel N.
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A DOUBLE-BLIND, PLACEBO CONTROLLED,PHASE II CHEMOIMMUNOTHERAPY (PACLITAXEL CARBOPLATIN-OREGOVOMAB) VS CHEMOTHERAPY (PACLITAXEL-CARBOPLATIN-PLACEBO) AS NEOADJUVANT THERAPY INPATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CARCINOMA
    Bhatt, Niraj
    Korant, Rajesh
    Kalloli, Mahesh
    Ramesh, Anita
    Kumar, Vijay
    Ganesan, T. S.
    Ravishankar, B.
    Pavithran, K.
    Kandipalli, Shilpa
    Yoon, Evelyn
    Yoon, Ben
    Teja, Tl Raj
    Gupta, Sunil
    Jada, Srinivasa Rao
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A251 - A251
  • [38] Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma
    Safra, Tamar
    Menczer, Joseph
    Bernstein, Rinat Molho
    Shpigel, Shulem
    Matcejevsky, Dianna
    Inbar, Moshe J.
    Golan, Abraham
    Grisaru, Dan
    Levy, Tally
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 215 - 218
  • [39] Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients
    Tangjitgamol, S
    See, HT
    Manusirivithaya, S
    Levenback, CF
    Gershenson, DM
    Kavanagh, JJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (05) : 804 - 814
  • [40] A comparison of patterns of failure between patients with ovarian, fallopian tube, or primary peritoneal carcinoma undergoing intravenous versus intraperitoneal chemotherapy
    Neubauer, N.
    Berry, E.
    Catanzarite, T.
    Schink, J.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S66 - S66
12345